Erasca: Revolution's Approval Just Took Risk Out Of The Fast Follower
Erasca (ERAS) is now a fully funded fast follower in RAS-targeted oncology, with ~$1B pro forma liquidity and three potential registration-enabling trials ahead. Daraxonrasib's FDA approval validates the RAS mechanism, shifting competition to tolerability and dose intensity, where ERAS-0015 shows potential differentiation. ERAS-0015 demonstrates strong tolerability, no dose-limiting toxicities, and high dose intensity, supporting its case for durable efficacy in key indications.
Erasca, Inc. (ERAS) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Erasca, Inc. (ERAS) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Erasca: A Credible Rival To Revolution's Daroxonrasib, At A Cheaper Price Point
Erasca, Inc. offers exposure to the RAS/MAPK oncology space at a fraction of Revolution Medicines' valuation, with a $6.7bn market cap versus RVMD's $38.5bn. ERAS-0015's Phase 1 data show promising efficacy and safety, with higher response rates and lower severe adverse events compared to Revolution's daraxonrasib. Patent infringement allegations from Revolution and a patient death initially pressured ERAS, but recent data, a Merck collaboration, and a $632.5m raise have driven a sharp recovery.
Erasca Touts 'Eye-Popping' ERAS-0015 Lung Cancer Data, FDA Path at BofA Conference
Erasca NASDAQ: ERAS executives said the company sees multiple potential development paths for its RAS-targeting portfolio, highlighting early clinical activity for ERAS-0015 in lung, pancreatic and colorectal cancers during a Bank of America biotech conference session.
Erasca, Inc. (ERAS) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Erasca, Inc. (ERAS) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Erasca: 'Hold' On Substantial RAS Targeting ERAS-0015 But With Two Key Risks
I initiate Erasca (ERAS) with a "Hold" rating due to promising phase 1 ERAS-0015 data but significant risks. ERAS-0015 showed high ORR in KRAS-mutant NSCLC [64%] and PDAC [50%] at RDE but faces safety and patent litigation risks. Company has strong cash reserves, global rights to ERAS-0015, and a Merck supply collaboration agreement for combination trials.
Buy These 3 Clinical-Stage Biotechs Under $30 With Solid Cash Runways
Clinical-stage biotech is one of the few corners of the market where a sub-$30 share price genuinely matters: small-cap oncology names can re-rate violently around a single Phase 3 readout or FDA decision, and 2026 is stacked with catalysts.
Erasca Stock Sinks 50% in Race for ‘Miracle' Cancer Drug. What's Behind the Historic Sell-Off.
Erasca is developing a competitor to Revolution Medicines' daraxonrasib.
Erasca, Inc. (ERAS) Discusses Preliminary Phase I Data and Differentiation of Pan-RAS Molecular Glue ERAS-0015 Transcript
Erasca, Inc. (ERAS) Discusses Preliminary Phase I Data and Differentiation of Pan-RAS Molecular Glue ERAS-0015 Transcript
uniQure, Syndax and Erasca Are Drawing Analyst Interest Ahead of Key Drug Catalysts
Wall Street is turning constructive on three clinical-stage biotechs simultaneously, each sitting at the edge of a binary catalyst.
Erasca Stock Surges 42% in a Week: Here's What You Should Know
ERAS stock jumps 42% in a week after early phase I solid tumors study data for ERAS-0015 shows encouraging responses, favourable safety and faster-than-expected enrollment.
Erasca, Inc.: Carving A Different Niche In RAS Signaling
Erasca, Inc. focuses on developing novel targeted therapies for solid tumors, particularly through the RAS/MAP kinase pathway, with a promising yet early-stage pipeline. The company's lead program, naporafenib, shows preliminary efficacy in NRAS-mutant melanoma, with key phase 3 data expected in 2025. Financially stable with a cash runway into at least 2027, Erasca can advance its pipeline without immediate funding concerns, mitigating dilution risk.
